These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 38351070)

  • 1. Leveraging Lymphatic System Targeting in Systemic Lupus Erythematosus for Improved Clinical Outcomes.
    Babalola KT; Arora M; Ganugula R; Agarwal SK; Mohan C; Kumar MNVR
    Pharmacol Rev; 2024 Feb; 76(2):228-250. PubMed ID: 38351070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphatic Drug Transport and Associated Drug Delivery Technologies: A Comprehensive Review.
    Punjabi MS; Naha A; Shetty D; Nayak UY
    Curr Pharm Des; 2021; 27(17):1992-1998. PubMed ID: 33272166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cracking the intestinal lymphatic system window utilizing oral delivery vehicles for precise therapy.
    Miao YB; Xu T; Gong Y; Chen A; Zou L; Jiang T; Shi Y
    J Nanobiotechnology; 2023 Aug; 21(1):263. PubMed ID: 37559085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of pharmaceutical care for drug treatment adherence in patients with systemic lupus erythematosus in Rio de Janeiro, Brazil: study protocol for a randomized controlled trial.
    Oliveira-Santos M; Verani JF; Camacho LA; de Andrade CA; Ferrante-Silva R; Klumb EM
    Trials; 2016 Apr; 17():181. PubMed ID: 27038611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in combination of microneedles and nanomedicines for lymphatic targeted drug delivery.
    Permana AD; Nainu F; Moffatt K; Larrañeta E; Donnelly RF
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 May; 13(3):e1690. PubMed ID: 33401339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A highly potent lymphatic system-targeting nanoparticle cyclosporine prevents glomerulonephritis in mouse model of lupus.
    Ganugula R; Arora M; Zou D; Agarwal SK; Mohan C; Kumar MNVR
    Sci Adv; 2020 Jun; 6(24):eabb3900. PubMed ID: 32582860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multifunctional nanocarriers for targeted drug delivery and diagnostic applications of lymph nodes metastasis: a review of recent trends and future perspectives.
    Lan HR; Zhang YN; Han YJ; Yao SY; Yang MX; Xu XG; Mou XZ; Jin KT
    J Nanobiotechnology; 2023 Aug; 21(1):247. PubMed ID: 37528366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-Based Nanocarriers for Lymphatic Transportation.
    Vishwakarma N; Jain A; Sharma R; Mody N; Vyas S; Vyas SP
    AAPS PharmSciTech; 2019 Jan; 20(2):83. PubMed ID: 30673895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs.
    Managuli RS; Raut SY; Reddy MS; Mutalik S
    Expert Opin Drug Deliv; 2018 Aug; 15(8):787-804. PubMed ID: 30025212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical approaches to colon targeted drug delivery systems.
    Chourasia MK; Jain SK
    J Pharm Pharm Sci; 2003; 6(1):33-66. PubMed ID: 12753729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphatic targeting for therapeutic application using nanoparticulate systems.
    Singh N; Handa M; Singh V; Kesharwani P; Shukla R
    J Drug Target; 2022 Dec; 30(10):1017-1033. PubMed ID: 35722764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport.
    Elz AS; Trevaskis NL; Porter CJH; Bowen JM; Prestidge CA
    J Control Release; 2022 Jan; 341():676-701. PubMed ID: 34896450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of lymphatic transport in enhancing oral protein and peptide drug delivery.
    Wasan KM
    Drug Dev Ind Pharm; 2002 Oct; 28(9):1047-58. PubMed ID: 12455465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphatic Delivery of Anti-HIV Drug Nanoparticles.
    Nayak Y; Avadhani K; Mutalik S; Nayak UY
    Recent Pat Nanotechnol; 2016; 10(2):116-27. PubMed ID: 27502389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles.
    Cai S; Yang Q; Bagby TR; Forrest ML
    Adv Drug Deliv Rev; 2011 Sep; 63(10-11):901-8. PubMed ID: 21712055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of the immune system in systemic lupus erythematosus.
    Ramanujam M; Davidson A
    Expert Rev Mol Med; 2008 Jan; 10():e2. PubMed ID: 18205972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced lupus erythematosus: incidence, management and prevention.
    Chang C; Gershwin ME
    Drug Saf; 2011 May; 34(5):357-74. PubMed ID: 21513360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous drug-induced lupus erythematosus: Clinical and immunological characteristics and update on new associated drugs.
    Bataille P; Chasset F; Monfort JB; De Risi-Pugliese T; Soria A; Francès C; Barbaud A; Senet P
    Ann Dermatol Venereol; 2021 Dec; 148(4):211-220. PubMed ID: 34711400
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.